Physiologically based pharmacokinetic (PBPK) modeling of interstrain variability in trichloroethylene metabolism in the mouse

Environmental Health Perspectives

Volumn 122, Issue 5, 2014, Pages 456-463

  Chiu, Weihsueh A ^a   Campbell Jr , Jerry L ^b   Clewell III, Harvey J ^b   Zhou, Yi Hui ^c   Wright, Fred A ^c   Guyton, Kathryn Z ^a   Rusyn, Ivan ^d  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

^d University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICHLOROACETIC ACID; S (1, 2 DICHLOROVINYL) CYSTEINE; TRICHLOROETHYLENE; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAYES THEOREM; GENETIC VARIABILITY; GLUTATHIONE METABOLISM; HEALTH HAZARD; HISTOGRAM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RELIABILITY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SIMULATION; ANIMAL; HUMAN; METABOLISM;

ANIMALS; BAYES THEOREM; DICHLOROACETIC ACID; HUMANS; MALE; MICE; TRICHLOROETHYLENE;

EID: 84899719458     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1307623     Document Type: Article

References (22)

1. Bois F.Y. 2000. Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics. Environ Health Perspect 108(suppl 2):307-316.
2. Bradford B. U, Lock EF, Kosyk O, Kim S, Uehara T, Harbourt D, et al. 2011. Interstrain differences in the liver effects of trichloroethylene in a multistrain panel of inbred mice. Toxicol Sci 120(1):206-217.
3. Chiu W. A, Jinot J, Scott CS, Makris SL, Cooper GS, Dzubow RC, et al. 2013. Human health effects of trichloroethylene: key findings and scientific issues. Environ Health Perspect 121:303-311; doi:10.1289/ehp.1205879.
4. Chiu W. A, Okino MS, Evans MV. 2009. Characterizing uncertainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approach. Toxicol Appl Pharmacol 241(1):36-60.
5. Clewell H. J, Gentry PR, Covington TR, Sarangapani R, Teeguarden J.G. 2004. Evaluation of the potential impact of age-and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol Sci 79(2):381-393.
6. Dorne J. L, Amzal B, Bois F, Crepet A, Tressou J, Verger P. 2012. Population effects and variability. Methods Mol Biol 929:521-581.
7. Evans M. V, Chiu WA, Okino MS, Caldwell JC. 2009. Development of an updated PBPK model for trichloroethylene and metabolites in mice, and its application to discern the role of oxidative metabolism in TCE-induced hepatomegaly. Toxicol Appl Pharmacol 236(3):329-340.
8. Guha N., Loomis D, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V., et al. 2012. Carcinogenicity of trichloroethylene, tetrachloroethylene, some other chlorinated solvents, and their metabolites. Lancet Oncol 13(12):1192-1193.
9. Hack C. E, Chiu WA, Jay ZQ, Clewell HJ. 2006. Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites. Regul Toxicol Pharmacol 46(1):63-83.
10. Hattis D., Lynch MK. 2007. Empirically observed distributions of pharmacokinetic and pharmacodynamic variability in humans-Implications for the derivation of single point component uncertainty factors providing equivalent protection as existing RfDs. In: Toxicokinetics in Risk Assessment (Lipscomb JC, Ohanian EV, eds). New York:Informa Healthcare, 69-93.
11. Kim S., Collins LB, Boysen G, Swenberg JA, Gold A, Ball LM, et al. 2009a. Liquid chromatography electrospray ionization tandem mass spectrometry analysis method for simultaneous detection of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-l-cysteine. Toxicology 262(3):230-238.
12. Kim S., Kim D, Pollack GM, Collins LB, Rusyn I. 2009b. Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-l-cysteine. Toxicol Appl Pharmacol 238(1):90-99.
13. Lash L. H, Fisher JW, Lipscomb JC, Parker JC. 2000. Metabolism of trichloroethylene. Environ Health Perspect 108(suppl 2):177-200.
14. Lock E. F, Abdo N, Huang R, Xia M, Kosyk O, O'Shea SH, et al. 2012. Quantitative high-throughput screening for chemical toxicity in a population-based in vitro model. Toxicol Sci 126(2):578-588.
15. NRC (National Research Council). 2006. Assessing the Human Health Risks of Trichloroethylene: Key Scientific Issues. Washington, DC:National Academies Press.
16. NRC (National Research Council). 2009. Science and Decisions: Advancing Risk Assessment. Washington, DC:National Academies Press.
17. O'Shea SH, Schwarz J, Kosyk O, Ross PK, Ha MJ, Wright FA, et al. 2011. In vitro screening for population variability in chemical toxicity. Toxicol Sci 119(2):398-407.
18. Rusyn I., Gatti DM, Wiltshire T, Kleeberger SR, Threadgill DW. 2010. Toxicogenetics: population-based testing of drug and chemical safety in mouse models. Pharmacogenomics 11(8):1127-1136.
19. Stedeford T., Zhao QJ, Dourson ML, Banasik M, Hsu CH. 2007. The application of non-default uncertainty factors in the U.S. EPA's Integrated Risk Information System (IRIS). Part I: UF(L), UF(S), and "other uncertainty factors. " J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 25(3):245-279.
20. U.S. EPA (U.S. Environmental Protection Agency). 2011. Toxicological Review of Trichloroethylene (CAS No. 79-01-6): In Support of Summary Information on the Integrated Risk Information System (IRIS). EPA/635/R-09/011F. Washington, DC:U.S. EPA. Available: http://www. epa.gov/iris/toxreviews/0199tr/0199tr.pdf [accessed: 13 March 2014].
21. Wetmore B. A, Wambaugh JF, Ferguson SS, Li L, Clewell HJ III, Judson R. S, et al. 2013. Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays. Toxicol Sci 132(2):327-346.
22. Zeise L., Bois FY, Chiu WA, Hattis D, Rusyn I, Guyton KZ. 2013. Addressing human variability in next-generation human health risk assessments of environmental chemicals. Environ Health Perspect 121:23-31; doi:10.1289/ ehp.1205687.